Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levofloxacin

FDA-approved product (tablet, oral), marketed as Iquix, Levaquin, Levaquin In Dextrose 5% In Plastic Container and 3 more.

Registered studies
50+
Lab records
143
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Levofloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Chronic bronchitis
  • Cystic fibrosis
  • Eye infection
  • Infection
  • Pneumonia
  • Respiratory tract infectious disorder
  • Sinusitis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
FDA pharmacologic class
Fluoroquinolone Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA12; WHO ATC S01AE05; FDA class Fluoroquinolone Antibacterial

Repurposing investigation

Levofloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis91.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 7 of 7 lab records
  • K. pneumoniae: measured active in 128 of 131 lab records
  • M. tuberculosis: measured active in 4 of 4 lab records
Open Levofloxacin in ChEMBL Registered studies below
Show the 143 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levofloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Initial Management of MRONJ Stages I and II, a Clinical Trial With Detection of Salivary Biomarkers

    NCT04584840 · start 2020-11-01

    Registered record
    Registry ID
    NCT04584840
    Conditions
    Osteonecrosis of the Jaw, Bisphosphonate Induced; Osteonecrosis of the Jaw, Bisphosphonate Related
    Interventions
    Surgical treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-11-01
    Completion
    2024-01-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteonecrosis of the Jaw, Bisphosphonate Induced; Osteonecrosis of the Jaw, Bisphosphonate Related
    InterventionSurgical treatment
    PhaseNot applicable
    Registry statusUnknown

  • Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection

    NCT04332848 · start 2020-07-28

    Registered record
    Registry ID
    NCT04332848
    Conditions
    Helicobacter Pylori Infection
    Interventions
    ET; SGT
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2020-07-28
    Completion
    2026-12
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionET; SGT
    PhasePhase 4
    Registry statusRecruiting

  • Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer

    NCT04204382 · start 2019-12-12

    Registered record
    Registry ID
    NCT04204382
    Conditions
    Radiation-induced Oral Mucositis
    Interventions
    Levofloxacin Injection; Compound Kushen Injection（CKI）
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-12-12
    Completion
    2022-12-30
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRadiation-induced Oral Mucositis
    InterventionLevofloxacin Injection; Compound Kushen Injection（CKI）
    PhasePhase 4
    Registry statusUnknown

  • Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication

    NCT03802318 · start 2019-01-02

    Registered record
    Registry ID
    NCT03802318
    Conditions
    Helicobacter Pylori Infection; Helicobacter Gastritis; Helicobacter-Associated Pyloric Ulcer
    Interventions
    Rabeprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-01-02
    Completion
    2020-12
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Helicobacter Gastritis; Helicobacter-Associated Pyloric Ulcer
    InterventionRabeprazole
    PhaseNot applicable
    Registry statusUnknown

  • Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection

    NCT03565484 · start 2019-01-01

    Registered record
    Registry ID
    NCT03565484
    Conditions
    Helicobacter Pylori Infection
    Interventions
    susceptibility guided therapy; personal medication history guided therapy; salvage treatment for failed eradication
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-01-01
    Completion
    2020-06-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionsusceptibility guided therapy; personal medication history guided therapy; salvage treatment for failed eradication
    PhasePhase 4
    Registry statusUnknown

  • Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients

    NCT03594149 · start 2018-07-18

    Registered record
    Registry ID
    NCT03594149
    Conditions
    Myelodysplastic Syndromes; Acute Myeloid Leukemia
    Interventions
    Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-07-18
    Completion
    2024-12-29
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes; Acute Myeloid Leukemia
    InterventionLevofloxacin
    PhasePhase 3
    Registry statusCompleted

  • Fluoroquinolone Associated Disability

    NCT03535558 · start 2018-05-17

    Registered record
    Registry ID
    NCT03535558
    Conditions
    Bronchitis; Sinusitis; Urinary Tract Infections
    Interventions
    Fluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-05-17
    Completion
    2018-12-31
    Enrolment
    239,306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchitis; Sinusitis; Urinary Tract Infections
    InterventionFluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects

    NCT03519516 · start 2018-01-25

    Registered record
    Registry ID
    NCT03519516
    Conditions
    Conjunctivitis; Conjunctivitis, Bacterial
    Interventions
    PRO-174; Sophixín Ofteno®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-25
    Completion
    2018-06-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConjunctivitis; Conjunctivitis, Bacterial
    InterventionPRO-174; Sophixín Ofteno®
    PhasePhase 1
    Registry statusCompleted

  • Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994

    NCT03395249 · start 2017-10-20

    Registered record
    Registry ID
    NCT03395249
    Conditions
    Healthy Volunteers
    Interventions
    SPR994; Placebo Oral Tablet; Orapenem®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-20
    Completion
    2018-08-02
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionSPR994; Placebo Oral Tablet; Orapenem®
    PhasePhase 1
    Registry statusCompleted

  • Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis

    NCT03234296 · start 2017-08-09

    Registered record
    Registry ID
    NCT03234296
    Conditions
    Acute Appendicitis
    Interventions
    Ertapenem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2017-08-09
    Completion
    2029-08-30
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis
    InterventionErtapenem; Placebo
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment

    NCT02988089 · start 2017-04-20

    Registered record
    Registry ID
    NCT02988089
    Conditions
    Helicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    Interventions
    Clarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ); proton pump inhibitor (PPI) and Colloidal Bismuth Pectin; amoxicillin and clarithromycin or amoxicillin and furazolidone; amoxicillin and furazolidone or amoxicillin and tetracycline; amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-04-20
    Completion
    2017-09
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    InterventionClarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ); proton pump inhibitor (PPI) and Colloidal Bismuth Pectin; amoxicillin and clarithromycin or amoxicillin and furazolidone +2 more
    PhasePhase 4
    Registry statusUnknown

  • Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis

    NCT03236961 · start 2017-04-03

    Registered record
    Registry ID
    NCT03236961
    Conditions
    Acute Appendicitis
    Interventions
    Ertapenem; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2017-04-03
    Completion
    2029-04-01
    Enrolment
    552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis
    InterventionErtapenem; Moxifloxacin
    PhaseNot applicable
    Registry statusActive not recruiting

  • The Effect of Colistin Inhalation on Ventilator Associated Pneumonia

    NCT03622450 · start 2016-01-02

    Registered record
    Registry ID
    NCT03622450
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    Colistin; Carbapenem + Aminoglycoside/ Quinolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-01-02
    Completion
    2018-01-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionColistin; Carbapenem + Aminoglycoside/ Quinolone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Treatment Shortening of MDR-TB Using Existing and New Drugs

    NCT02619994 · start 2016-01

    Registered record
    Registry ID
    NCT02619994
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Linezolid; Delamanid; Levofloxacin; Pyrazinamide; Locally-used WHO-approved MDR-TB regimen in Korea
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-01
    Completion
    2021-06
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionLinezolid; Delamanid; Levofloxacin; Pyrazinamide +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Two Week Nitazoxanidebased Quadruple Regimen

    NCT02621359 · start 2015-01

    Registered record
    Registry ID
    NCT02621359
    Conditions
    Dyspepsia
    Interventions
    Nitazoxanide; Levofloxacin; Doxycyclin; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2022-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyspepsia
    InterventionNitazoxanide; Levofloxacin; Doxycyclin; Omeprazole
    PhasePhase 3
    Registry statusUnknown